EGFRgene Copy Number Predicts Response to Anti-Egfr Treatment inRASwild Type andRAS/BRAF/PIK3CAwild Type Metastatic Colorectal Cancer

International Journal of Cancer - United States
doi 10.1002/ijc.30507
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

EGFR Gene Copy Number Assessment From Areas With Highest EGFR Expression Predicts Response to Anti-Egfr Therapy in Colorectal Cancer

British Journal of Cancer
Cancer ResearchOncology
2011English

Plasma HER2 (ERBB2) Copy Number Predicts Response to HER2-targeted Therapy in Metastatic Colorectal Cancer

Clinical Cancer Research
Cancer ResearchOncology
2019English

HER2 Positivity Predicts Unresponsiveness to EGFR‐Targeted Treatment in Metastatic Colorectal Cancer

Oncologist
Cancer ResearchMedicineOncology
2019English

HER2 Gene Copy Number Status May Influence Clinical Efficacy to Anti-Egfr Monoclonal Antibodies in Metastatic Colorectal Cancer Patients

British Journal of Cancer
Cancer ResearchOncology
2013English

Pilot Trial of Combined BRAF and EGFR Inhibition in BRAF-Mutant Metastatic Colorectal Cancer Patients

Clinical Cancer Research
Cancer ResearchOncology
2015English

Prevalence of KRAS, BRAF, PI3K and EGFR Mutations Among Asian Patients With Metastatic Colorectal Cancer

Oncology Letters
Cancer ResearchOncology
2015English

RAS and BRAF in Metastatic Colorectal Cancer Management

Journal of Gastrointestinal Oncology
OncologyGastroenterology
2016English

Molecular Determinants of Anti-Egfr Sensitivity and Resistance in Metastatic Colorectal Cancer

British Journal of Cancer
Cancer ResearchOncology
2010English

EGFR Alterations and Response to Anti-Egfr Therapy: Is It a Matter of Gene Amplification or Gene Copy Number Gain?

British Journal of Cancer
Cancer ResearchOncology
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy